Recent Quotes (30 days)

You have no recent quotes
chg | %

Juno Therapeutics Inc  

(Public, NASDAQ:JUNO)   Watch this stock  
Find more results for JUNO
+0.39 (1.43%)
Real-time:   1:06PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.15 - 27.89
52 week 22.37 - 57.82
Open 27.48
Vol / Avg. 1.25M/2.23M
Mkt cap 2.87B
P/E     -
Div/yield     -
EPS -2.65
Shares 105.54M
Beta     -
Inst. own 72%
Aug 10, 2016
Q2 2016 Juno Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 7, 2016
Juno Therapeutics Inc Reports Clinical Hold on the JCAR015 Phase II ROCKET Trial Call - Webcast
Jun 16, 2016
Juno Therapeutics Inc Annual Shareholders Meeting
Jun 10, 2016
Juno Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2016
Juno Therapeutics Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 7, 2016
Juno Therapeutics Inc at Jefferies Healthcare Conference - Webcast
May 10, 2016
Juno Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 9, 2016
Q1 2016 Juno Therapeutics Inc Earnings Call - Webcast
May 9, 2016
Q1 2016 Juno Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -727.75% -1314.17%
Operating margin -817.40% -1340.10%
EBITD margin - -1273.86%
Return on average assets -19.44% -24.75%
Return on average equity -24.25% -31.29%
Employees 373 -
CDP Score - -


307 Westlake Ave N Ste 300
SEATTLE, WA 98109-5235
United States - Map
+1-206-5821600 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Juno Therapeutics, Inc. is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16/IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial for treatment of various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of adult myeloid leukemia, myelodysplasic syndrome and chronic myeloid leukemia.

Officers and directors

Howard H. Pien Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Hans Edgar Bishop President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Steven D. Harr M.D. Chief Financial Officer, Head of Corporate Development
Age: 45
Bio & Compensation  - Reuters
Hyam I. Levitsky M.D Executive vice president - Research, chief scientific officer
Age: 54
Bio & Compensation  - Reuters
Robert Azelby Executive Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Bernard J. Cassidy General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Hal V. Barron M.D. Independent Director
Age: 53
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Director
Age: 62
Bio & Compensation  - Reuters
Richard Klausner M.D. Director
Age: 64
Bio & Compensation  - Reuters
Marc Tessier-Lavigne Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters